Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 2 Triple Negative Breast Neoplasms 1 Refractory/Relapse Neuroblastoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, B-Cell 1 Kidney Neoplasms 1 Hodgkin Disease 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Paclitaxel 81 Trastuzumab 76 Fulvestrant 55 Cyclophosphamide 49 Capecitabine 42 Lapatinib 40 pembrolizumab 39 Docetaxel 38 palbociclib 36 Carboplatin 33 Letrozole 28 olaparib 23 Doxorubicin 23 Gemcitabine 21 Taxes 20 Everolimus 20 ribociclib 19 abemaciclib 19 Ado-Trastuzumab Emtansine 18 pertuzumab 17 Radiotherapy 17 Magnetic Resonance Spectroscopy 17 Bevacizumab 16 130-nm albumin-bound paclitaxel 16 exemestane 15 Vinorelbine 15 Cisplatin 15 veliparib 14 Biopsy 14 Alpelisib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Breast Neoplasms × Biological Products × Clear all

NCT04382352 2023-03-24

B002-101

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 1 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡